PR Newswire
SAN DIEGO, Sept. 20, 2018
SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be
presenting at the 2018 Cantor Global Healthcare Conference in New York on Monday, October 1 at 3:30 p.m. ET/12:30 p.m. PT.
Dr. Helen Torley, president and chief executive officer, will provide a corporate overview.
A live audio webcast of the presentation will be available in the "Investors" section of Halozyme's website at www.halozyme.com with an archived replay available for 90 days
following the event.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies
that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa
(PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug
therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the
potential to be used in combination with different types of cancer therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer,
Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion for its ENHANZE® drug delivery technology. Halozyme is
headquartered in San Diego. For more information visit www.halozyme.com.
Contacts:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
858-356-5932
robert.uhl@westwicke.com
Laurie Stelzer
858-704-8222
ir@halozyme.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-participate-in-upcoming-investor-conference-300716456.html
SOURCE Halozyme Therapeutics, Inc.
